Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity

• Status: Completed
• Trial end date: 2021-05-13
• Target enrollment: 0
• Participant gender: All

Summary

A Phase 1 Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Midazolam; Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Body Mass Index (BMI) ≥ 30.0 kg/m2 and not more than 45.4 kg/m2 at Screening.

• Stable body weight, defined as <5 kg change (per participant report) for 90 days before Screening

Exclusion Criteria:

• Known prior participation in a trial involving PF-06882961.

• Known intolerance or hypersensitivity to GLP-1R agonists.

• Known hypersensitivity to rosuvastatin or midazolam.

• Diagnosis of type 1 or type 2 diabetes mellitus or secondary forms of diabetes at screening. Note: prior diagnoses of gestational diabetes during pregnancy only are eligible if they meet the other eligibility criteria

• Any lifetime history of a suicide attempt.

• Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.

• Participation in a formal weight reduction program (eg, Weight Watchers) within 90 days prior to Screening.